Short-term and long-term efficacy of sublingual immunotherapy in different courses for house dust mite-induced allergic rhinitis

Yang, Jie; Zheng, Jing; Zhou, Yu; Qiu, Quan; Zhan, Jiabin; Wei, Xin

doi:10.1016/j.amjoto.2023.104118

Cited by 2 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were 12 persons accounting for 40% called early‐but‐not‐late responders who had a good early stage response, but this was not maintained on the long term.. Similar situation occurred with conventional immunotherapy, and several scholars like the Yuan and Yang also analyzed its poor long‐term efficacy and they found it resulted from an inadequate course of treatment or low maintenance dose 27,28 . While ILIT has been carried out in relevant clinical trials, in 2021 Weinfeld et al 29 .…”

Section: Discussionmentioning

confidence: 95%

“…Similar situation occurred with conventional immunotherapy, and several scholars like the Yuan and Yang also analyzed its poor long‐term efficacy and they found it resulted from an inadequate course of treatment or low maintenance dose. 27 , 28 While ILIT has been carried out in relevant clinical trials, in 2021 Weinfeld et al. 29 carried out a double‐blind placebo‐controlled randomized trial by administering ILIT pre‐season booster to AR patients with grass pollen allergy, and the findings confirmed that the booster improved the allergic reactions caused during the grass pollen season with lower side effects compared to placebo.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The long‐term efficacy of intra‐cervical lymphatic immunotherapy on adults with allergic rhinitis: A randomized controlled study

Qin,

Huang,

Zheng

et al. 2024

Clinical & Translational All

View full text Add to dashboard Cite

BackgroundThe efficacy and safety of the novel immunotherapy method, intra‐cervical lymphatic immunotherapy (ICLIT), need to be investigated. Comparing it with subcutaneous immunotherapy (SCIT), we clarified the long‐term efficacy and safety of intra‐cervical lymphatic immunotherapy on allergic rhinitis (AR), and investigated the improvement of clinical efficacy of the booster injection at 1 year after ICLIT treatment.MethodsNinety adult patients with dust mite allergy were randomly divided into 3 groups: 30 in the SCIT group, 30 in the ILCLIT group, and 30 in ICLIT booster group. Changes in total symptom score (TSS), nasal symptom score (TNSS), ocular symptom score (TOSS) and total medication score (TMS) were evaluated in the three groups. Adverse reactions were recorded, and serum dust mite specific IgE (sIgE) and specific IgG4 were assessed in the ICLIT group and ICLIT booster group.ResultsTSS, TNSS, TOSS, and TMS scores were significantly lower in the three groups at 36 months after treatment (p < 0. 05). And at 36 months the ICLIT‐booster group showed results similar to SCIT and superior to ICLIT (p < 0. 05). Serum specific IgE decreased in all three groups at 12 and 36 months after treatment, p < 0.01. The ICLIT group and the ICLIT booster group showed a significant increase in sIgG4, p < 0.01. None of the patients in the three groups had any serious systemic adverse effects during the 3‐year follow‐up.ConclusionThe ICLIT treatment is effective and safe on AR. One booster injection of allergens at 1 year can greatly improve its long‐term efficacy.Trial RegistryClinical trial registration number: ChiCTR1800017130.

show abstract

Section: Discussionmentioning

confidence: 95%